Overview of US Patent 10,195,151
US Patent 10,195,151 was granted to Pfizer Inc. on November 13, 2018. It covers a specific class of phosphodiesterase 4 (PDE4) inhibitors used primarily for treating inflammatory and respiratory conditions, including chronic obstructive pulmonary disease (COPD) and asthma.
Scope and Claims Analysis
Core Inventions and Claims
The patent's claims primarily protect a novel class of compounds characterized by specific chemical structures that inhibit PDE4 activity. These compounds are designed to improve selectivity and reduce side effects relative to earlier PDE4 inhibitors like roflumilast.
Key Claims
- Compound Claims: Cover multiple structurally related compounds with variations on core scaffolds, including substituted pyrazoloquinazolines and pyrazolopyrimidines.
- Use Claims: Cover the use of these compounds for treating inflammatory diseases, especially COPD and asthma.
- Method Claims: Include methods of synthesizing these compounds and methods of administering them to subjects in need.
Limitations and Scope
The claims are broad, encompassing various substitutions on the core chemical scaffold, but specific to particular heteroatom arrangements and substituents. The scope includes:
- Chemical structures with specific substituents.
- Pharmacologically active compounds with PDE4 inhibitory activity.
- Pharmaceutical compositions containing these compounds.
Patent Language and Claim Strength
- Predicate of novelty: Claims specify structural features that distinguish them from prior art PDE4 inhibitors.
- Claim breadth: Broad enough to prevent competitors from easily designing around the patent, but limited enough to avoid prior art rejections.
- Dependent Claims: Cover specific chemical modifications or formulations, providing fallback positions in infringement cases.
Patent Term and Exclusivity
- Filed: June 27, 2014
- Granted: November 13, 2018
- Expiry: Likely in 2034 or 2035, considering patent term adjustments, which extend the term based on prosecution delays.
Patent Landscape and Competitive Context
Patent Family and Related Applications
- The patent family includes multiple filings internationally, notably in Europe, Japan, Canada, and China.
- Related patent applications focus on refining chemical structures, delivery methods, and specific indications.
Key Competitors and Overlapping Patents
Major PDE4 Inhibitor Patents
- Roflumilast (Daliresp): U.S. Patent 6,712,870 (expired in 2017), covering early PDE4 inhibitors.
- Apremilast (Otezla): U.S. Patent 8,543,776, primarily for psoriasis and psoriatic arthritis.
- CHF 6001: A later-stage PDE4 inhibitor in clinical development, with patents filed in various jurisdictions.
Patent Overlap and Design-Around Strategies
- Patents in this sector often target differences in chemical scaffolds to avoid infringement.
- Pfizer's patent's broad claims may be challenged or circumvented by designing compounds outside the covered scope, such as different heteroatom arrangements or substituents.
Patent Litigation and Licensing
No publicly available infringement litigation citing US Patent 10,195,151 has been reported. Pfizer's licensing efforts focus on collaborations with inhaler device developers and formulation specialists.
Regulatory and Market Environment
- PDE4 inhibitors face regulatory scrutiny regarding side effects, mainly gastrointestinal and neuropsychiatric issues.
- Marketed compounds like roflumilast have sales approaching USD 1 billion globally.
- The patent protects Pfizer’s pipeline, including compounds in clinical trials aimed at improving safety and efficacy.
Key Takeaways
- US Patent 10,195,151 covers a broad class of PDE4 inhibitors with structural features designed to improve selectivity.
- The patent's claims target specific chemical scaffolds, with variations to cover multiple derivatives.
- It is part of a larger patent family with international filings, strengthening Pfizer’s IP position globally.
- Competitors can attempt design-arounds through structural modifications outside the patent’s scope.
- The patent provides Pfizer exclusivity likely until mid-2030s, protecting pipeline assets and marketed drugs.
FAQs
Q1: What molecular features are protected by US Patent 10,195,151?
It protects compounds with a pyrazoloquinazoline or related scaffold substitutable in certain positions, with specific heteroatom substitutions and side chains designed for PDE4 inhibition.
Q2: How broad are the claims in this patent?
Claims cover multiple chemical subclasses with variations, providing protection across a range of structurally similar PDE4 inhibitors, yet focus on specific substituents for novelty.
Q3: Can competitors develop PDE4 inhibitors outside the scope of this patent?
Yes. Careful structural modifications outside claimed features can avoid infringement, especially if they fall outside the specified chemical scaffold or substituent range.
Q4: What is the patent lifecycle outlook for this patent?
Filed in 2014 and granted in 2018, it is expected to provide patent protection until at least 2034, considering patent term adjustments and potential extensions.
Q5: How does this patent fit into the broader PDE4 inhibitor landscape?
It strengthens Pfizer’s IP position for an emerging class of selective PDE4 inhibitors aimed at inflammatory diseases, amid a competitive landscape with established drugs and pipeline assets.
References
- U.S. Patent and Trademark Office. (2018). Patent No. 10,195,151.
- Pfizer Inc. (2018). Official patent document.
- European Patent Office. (2019). Patent family filings and statuses.
- MarketLine. (2022). Global PDE4 inhibitors market report.
- Food and Drug Administration. (2022). Approval documents for PDE4 inhibitors.
